Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel plus dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Subcutaneous, Intradermal
01
Overview
Docetaxel plus dendritic cell vaccine is a combination therapy used primarily in oncology clinical trials. Docetaxel is a taxane-class small molecule chemotherapeutic agent that promotes the assembly of microtubules and stabilizes them by preventing depolymerization, thereby inhibiting mitosis and leading to cancer cell death[1][2][5]. Dendritic cell vaccines are a form of personalized immunotherapy where autologous monocytes are harvested from the patient, differentiated into dendritic cells ex vivo, loaded with tumor-associated antigens (often via mRNA transfection), matured to enhance immune activation properties, and then administered back to the patient[3][6]. The goal is to stimulate an antigen-specific T-cell response against tumor cells. This combination has been studied in metastatic castration-resistant prostate cancer (mCRPC) among other cancers; early-phase studies show it can induce immune responses with manageable toxicity profiles[3].
- Brand names
- Taxotere
- Other names
- DCvacautologous dendritic cell-based cancer vaccine
02
Targets
pMHC-II (Peptide-major histocompatibility complex class II complex)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on docetaxel plus dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel plus dendritic cell vaccine.